Charles River Laboratories International Inc.
Organization details
- Legal name
- Charles River Laboratories International Inc.
- Former names
- Charles River Laboratories Holdings Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 8731 — Services-Commercial Physical & Biological Research
- Headquarters city
- Wilmington
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CRL
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001100682
- EIN
- 06-1397316
- Wikidata ID
- Q5082076
Board of directors
-
Abraham Ceesay · DirectorSince 2025
-
Birgit Girshick · Director · Chief Executive OfficerSince 2026
-
C. Richard Reese · DirectorSince 2023
-
Craig B. Thompson · DirectorSince 2023
-
Deborah Turner Kochevar · DirectorSince 2023
-
George Llado Sr. · DirectorSince 2023
-
George Massaro · DirectorSince 2023
-
James C. Foster · Director · Chairman, President and CEOSince 2023
-
Mark J. Enyedy · DirectorSince 2025
-
Martin Mackay · DirectorSince 2023
-
Nancy C. Andrews · DirectorSince 2023
-
Paul W. Graves · DirectorSince 2025
-
Reshema Kemps-Polanco · DirectorSince 2024
-
Richard F. Wallman · DirectorSince 2023
-
Robert J. Bertolini · DirectorSince 2023
-
Steven Barg · DirectorSince 2025
-
Virginia M. Wilson · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.2%
-
96.7%
-
97.0%
-
98.6%
-
98.7%
-
98.8%
-
98.8%
-
98.9%
-
98.9%
-
99.6%
-
99.6%
-
99.9%
Board connections
10 of this board's directors also sit on 13 other boards. 9 are in the same sector.
- via Paul W. Graves
-
BioMarin Pharmaceutical Inc. Same sectorvia Mark J. Enyedy
- via Richard F. Wallman
-
Cardinal Health Inc. Same sectorvia Steven Barg
- via Virginia M. Wilson
-
Elanco Animal Health Incorporated Same sectorvia Deborah Turner Kochevar
-
Kailera Therapeutics Inc. Same sectorvia Martin Mackay
-
Maze Therapeutics Inc. Same sectorvia Nancy C. Andrews
-
Pacira BioSciences Inc. Same sectorvia Abraham Ceesay
-
Rallybio Corporation Same sectorvia Martin Mackay
-
Rapport Therapeutics Inc. Same sectorvia Abraham Ceesay
-
Regeneron Pharmaceuticals Inc. Same sectorvia Craig B. Thompson
- via Richard F. Wallman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $7,338
- 2 purchases by 2 insiders
- Sold, last 12 months
- $52,066,240
- 21 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 6, 2026 | Knell Michael Gunnar Officer (SVP, Finance and CAO) | Shares withheld for tax | −649 | $313.02 | $203,150 |
| Oct 22, 2026 | James C. Foster Director | Option exercise | +24,042 | $244.41 | $5,876,105 |
| Oct 22, 2026 | James C. Foster Director | Open-market sale | −24,042 | $350.00 | $8,414,700 |
| Oct 21, 2026 | Parisotto Shannon M Officer (CEVP, Disc & Safety Assessment) | Option exercise | +2,156 | $244.41 | $526,948 |
| Oct 21, 2026 | Parisotto Shannon M Officer (CEVP, Disc & Safety Assessment) | Open-market sale | −2,156 | $344.41 | $742,548 |
| Oct 5, 2026 | Parisotto Shannon M Officer (CEVP, Disc & Safety Assessment) | Option exercise | +981 | $208.44 | $204,480 |
| Oct 5, 2026 | Parisotto Shannon M Officer (CEVP, Disc & Safety Assessment) | Open-market sale | −981 | $308.44 | $302,580 |
| Sep 30, 2026 | Coleman Glenn Officer (EVP & Chief Financial Officer) | Open-market purchase | +10 | $297.43 | $2,974 |
| Aug 25, 2026 | James C. Foster Director | Option exercise | +21,132 | $194.12 | $4,102,144 |
| Aug 25, 2026 | James C. Foster Director | Option exercise | +12,429 | $208.44 | $2,590,701 |
| Aug 25, 2026 | James C. Foster Director | Open-market sale | −33,561 | $300.00 | $10,068,300 |
| Aug 19, 2026 | Parisotto Shannon M Officer (CEVP, Disc & Safety Assessment) | Option exercise | +2,039 | $194.12 | $395,811 |
| Aug 19, 2026 | Birgit Girshick Director, Officer (Chief Executive Officer) | Gift | −528 | — | — |
| Aug 19, 2026 | Parisotto Shannon M Officer (CEVP, Disc & Safety Assessment) | Open-market sale | −2,039 | $294.12 | $599,711 |
| Aug 18, 2026 | Nancy C. Andrews Director | Option exercise | +573 | $164.30 | $94,144 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Charles River Laboratories International Inc.
Who is the CEO of Charles River Laboratories International Inc.?
James C. Foster is Charles River Laboratories International Inc.'s Chairman, President and CEO.
How many directors are on Charles River Laboratories International Inc.'s board?
Charles River Laboratories International Inc.'s board has 17 directors: Abraham Ceesay, Birgit Girshick, C. Richard Reese, Craig B. Thompson, Deborah Turner Kochevar, George Llado Sr., George Massaro, James C. Foster, Mark J. Enyedy, Martin Mackay and 7 others.
Are Charles River Laboratories International Inc. insiders buying or selling shares?
Over the last 12 months, Charles River Laboratories International Inc. insiders bought $7,338 of shares in 2 purchases and sold $52.1 million of shares in 21 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="charles-river-laboratories-international-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.